FDA advisory panel says benefits of Kamra inlay outweigh risks

Article

The U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel recently determined that the benefits of AcuFocus’ Kamra inlay outweigh the risks for presbyopic patients.

Irvine, CA-The U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel recently determined that the benefits of AcuFocus’ Kamra inlay outweigh the risks for presbyopic patients.

The panel reviewed clinical data on 508 patients who received the inlay monocularly during the U.S. Investigational Device Exemption (IDE) clinical trial. Several Kamra patients and ophthalmologists also spoke to the panel about their experience with the inlay. Out of eight panelists, seven voted that Kamra is effective, but on the question of safety, the panel chairman had to break a tie by voting against. Ultimately, the panel voted that the benefits outweigh the risks, with four in favor, three against, and one abstention. 

The FDA will take the panel’s decision into consideration as a part of its own determination of the benefit-risk of the Pre-Market Approval (PMA) for Kamra.

The Kamra inlay is implanted into a patient’s non-dominant eye and uses the principle of small-aperture optics to improve near vision with minimal change in distance vision.  

Kamra has launched in 33 of the 50 countries in which it is already approved. More than 20,000 inlays have been implanted outside of the U.S., and 362 of those have been removed, most due to vision complaints. 

Next: BCLA names new president, announces winner of BCLA Industry Award 

AAOphth offers answers to common questions about cataracts

Study: using Avastin to treat AMD, DME could save Medicare billions

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.